NCT04913597 is a clinical trial in Corticosteroid-resistant or Relapsed ITP, sponsored by Peking University People's Hospital.

Who is sponsoring NCT04913597?

NCT04913597 is sponsored by Peking University People's Hospital.

What condition does NCT04913597 study?

NCT04913597 studies Corticosteroid-resistant or Relapsed ITP.

Is NCT04913597 still recruiting?

NCT04913597 is currently status unknown. Last updated 4 June 2021.

Last reviewed 2021-06-04 · How we verify

NCT04913597

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Switching Avatrombopag and Rh-TPO in ITP

Status unknown Last updated 4 June 2021

What this trial tests

trial in Corticosteroid-resistant or Relapsed ITP in 100 participants. Status unknown.

Timeline

20 June 2021

Primary endpoint
31 December 2022

31 December 2023

Quick facts

Lead sponsor	Peking University People's Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	20 June 2021
Primary completion	31 December 2022
Estimated completion	31 December 2023

Conditions studied

Corticosteroid-resistant or Relapsed ITP — all drugs for Corticosteroid-resistant or Relapsed ITP →

Sponsor

Peking University People's Hospital

Who can join

Adults 18 to 75, any sex, with Corticosteroid-resistant or Relapsed ITP. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Thrombopoietin receptor agonists (TPO-RAs) represent a highly effective and well-tolerated second-line ITP treatment that provides excellent responses.If there is cross-resistance between 2 drugs for the treatment of adult ITP is still unkonwn.The purpose of this study is to investigate the efficacy and safety of switching avatrombopag and rh-TPO in adults with ITP.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04913597 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 4 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04913597.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing